Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction

BMC Cardiovascular Disorders

David Erlinge¹  Sten Blomquist²  Anna Spencer²  Patrik Gilje¹  Kazuma Miyazu¹  J Gustav Smith³  Olof Gidlöf¹ 

[1] Department of Cardiology, Faculty of Medicine, Lund University, Skåne University Hospital, SE-221 00, Box 117, Lund, Sweden;Department of Cardiothoracic Surgery, Anaesthesia and Intensive Care, Faculty of Medicine, Lund University, Lund, Sweden;Broad Institute of Harvard and MIT, Cambridge, MA, USA

关键词: Prognosis;    Biomarker;    Acute coronary syndrome;    Myocardial infarction;    MiRNA;   

Others  :  857836
DOI  :  10.1186/1471-2261-13-12

 received in 2012-09-28, accepted in 2013-02-25,  发布年份 2013

【 摘 要 】

Background

Increased levels of cardio-enriched microRNAs (miRNAs) have been described in patients with myocardial infarction (MI). We wanted to evaluate the diagnostic and prognostic potential of cardio-enriched miRNAs in patients presenting with a suspected acute coronary syndrome (ACS).

Methods

Cardio-enriched miRNAs (miR-1, miR-208b and miR-499-5p) were measured using real time PCR in plasma samples from 424 patients with suspected ACS treated in a coronary care unit. miRNAs were assessed for discrimination of a clinical diagnosis of myocardial infarction and for association with 30-day mortality and diagnosis of heart failure. Correlation with left ventricular systolic dysfunction as measured by the ejection fraction (LVEF) was also assessed. To confirm myocardial origin miRNA was measured during coronary artery bypass surgery.

Results

miRNAs were higher in MI patients and correlated with LVEF (p < 0.001). Discrimination of MI was accurate for miR-208b (AUC = 0.82) and miR-499-5p (AUC = 0.79) but considerable lower than for Troponin T (AUC = 0.95). Increased miRNA levels were strongly associated with increased risk of mortality or heart failure within 30 days for miR-208b (OR 1.79, 95% CI = 1.38-2.23, p = 1 × 10^-5) and miR-499-5p (OR 1.70, 95% CI = 1.31-2.20, p = 5 × 10^-5) but the association was lost when adjusting for Troponin T. During surgery miR-208b and miR-499-5p was released in the coronary sinus after cardioplegia-reperfusion to markedly higher levels than in a peripheral vein.

Conclusions

Our findings confirm increased levels of cardio-enriched miRNAs in the blood of MI patients and establish association of increased miRNA levels with reduced systolic function after MI and risk of death or heart failure.

【 授权许可】

   
2013 Gidlöf et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Ambros V: The functions of animal microRNAs. Nature 2004, 431(7006):350-355.
• [2]Filipowicz W, Bhattacharyya SN, Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008, 9(2):102-114.
• [3]Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233.
• [4]Wienholds E, Plasterk RH: MicroRNA function in animal development. FEBS Lett 2005, 579(26):5911-5922.
• [5]Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al.: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129(7):1401-1414.
• [6]Berezikov E, Thuemmler F, van Laake LW, Kondova I, Bontrop R, Cuppen E, Plasterk RH: Diversity of microRNAs in human and chimpanzee brain. Nat Genet 2006, 38(12):1375-1377.
• [7]van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA, Kelm RJ Jr, Olson EN: A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009, 17(5):662-673.
• [8]Zhao Y, Samal E, Srivastava D: Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436(7048):214-220.
• [9]Williams AH, Liu N, van Rooij E, Olson EN: MicroRNA control of muscle development and disease. Curr Opin Cell Biol 2009, 21(3):461-469.
• [10]Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, et al.: Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008, 105(6):2111-2116.
• [11]Dimmeler S, Zeiher AM: Circulating microRNAs: novel biomarkers for cardiovascular diseases? Eur Heart J 2010, 31(22):2705-2707.
• [12]Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9(6):654-659.
• [13]Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Koppel T, Jahantigh MN, Lutgens E, et al.: Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009, 2(100):ra81.
• [14]Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, Sina JF, Fare TL, Sistare FD, et al.: Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009, 55(11):1977-1983.
• [15]Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N: Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009, 55(11):1944-1949.
• [16]Gupta SK, Bang C, Thum T: Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc genet 2010, 3(5):484-488.
• [17]Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O: Serum levels of microRNAs in patients with heart failure. Eur J Hear Fail 2012, 14(2):147-154.
• [18]Seto AG, van Rooij E: Circulating microRNAs to identify human heart failure. Eur J Hear Fail 2012, 14(2):118-119.
• [19]Gu YL, Voors AA, Zijlstra F, Hillege HL, Struck J, Masson S, Vago T, Anker SD, van den Heuvel AF, van Veldhuisen DJ, et al.: Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol 2011, 100(12):1069-1076.
• [20]Agewall S, Giannitsis E, Jernberg T, Katus H: Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 2011, 32(4):404-411.
• [21]D’Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, Rubino M, Carena MC, Spazzafumo L, De Simone M, et al.: Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010, 31(22):2765-2773.
• [22]Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, Nonogi H, Iwai N: Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem 2010, 56(7):1183-1185.
• [23]Gidlof O, Andersson P, van der Pals J, Gotberg M, Erlinge D: Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011, 118(4):217-226.
• [24]Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, Li K, Yu B, Li Z, Wang R, et al.: Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010, 391(1):73-77.
• [25]De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM: Transcoronary concentration gradients of circulating microRNAs. Circulation 2011, 124(18):1936-1944.
• [26]Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, Kempf T, Wollert KC, Thum T: Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011, 51(5):872-875.